PremiumThe FlyAcrivon Therapeutics price target lowered to $9 from $10 at Oppenheimer Optimistic Outlook for Acrivon Therapeutics: Promising ACR-368 Results and Strategic Focus on Endometrial Cancer Acrivon Therapeutics reports Q1 EPS (51c), consensus (65c) PremiumThe FlyBiotech Alert: Searches spiking for these stocks today Acrivon Therapeutics Reports Progress in Cancer Drug Development Acrivon Therapeutics Appoints New Chief Medical Officer PremiumThe FlyAcrivon Therapeutics reports Q4 EPS (60c), consensus (70c) Acrivon Therapeutics Reports 2024 Financial Results and Progress Promising Phase 2 Results for ACR-368 in Endometrial Cancer Justify Buy Rating 
